May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
National Estimates of the Prevalence and Distribution of Open–Angle Glaucoma by Age and Gender in the United States Based on the Medical Expenditure Panel Survey
Author Affiliations & Notes
  • M.A. Mychaskiw
    Worldwide Outcomes Research, Pfizer Inc., New York, NY
  • G.F. Schwartz
    Greater Baltimore Medical Center, Johns Hopkins University, Baltimore, MD
  • Footnotes
    Commercial Relationships  M.A. Mychaskiw, Pfizer Inc., E; G.F. Schwartz, Pfizer, Allergan, Santen, F; Pfizer, Merck, R.
  • Footnotes
    Support  Supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3447. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.A. Mychaskiw, G.F. Schwartz; National Estimates of the Prevalence and Distribution of Open–Angle Glaucoma by Age and Gender in the United States Based on the Medical Expenditure Panel Survey . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3447.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To estimate the prevalence and distribution of open–angle glaucoma (OAG) by age and gender in the United States using the Medical Expenditure Panel Survey (MEPS).

Methods: : A retrospective analysis was performed using data in the 2001 MEPS. MEPS collected and combined survey and administrative claims data from a nationally representative sample of 33,556 respondents and from health care and insurance providers. Data used in the present study included age, gender, medical conditions, and utilization of medical care. Patients with OAG were identified by ICD–9–CM codes. Sample estimates were weighted and projected to the population; 95% confidence limits (CL) were calculated using the Taylor expansion method.

Results: : The estimated prevalence of OAG was 1.35% (95% CL=1.07%–1.63%) or 3,837,339 individuals in the population. The prevalence in those 40–59 years old and >60 years old was estimated as 1.34% and 1.94%, respectively. OAG was distributed approximately equally between men and women, estimated as 1.38% (95% CL=0.94%–1.82%) and 1.32% (95% CL=0.94%–1.71%), respectively.

Conclusions: : Differences in experimental designs and sampling frames demonstrate a range of estimates of the prevalence of OAG in the US from 1.86% to 4.74%. The findings of the present study are congruous with and reasonably approximate estimates below 2%. This secondary data souce corroborates the prevalence of OAG increasing with age, and the rate was similar in men and women. Secondary sources of nationally representative data may be useful in estimating the prevalence and distribution of diseases such as OAG in the US, and the data derived may have the potential ability to help allocate scarce resources toward ocular health and the preservation of visual function.

Keywords: clinical (human) or epidemiologic studies: prevalence/incidence • clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×